ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
27 announcements
Beta Drugs secured Azerbaijani regulatory approvals for its oncology portfolio across multiple dosage forms. The company targets Azerbaijan commercialisation during the current financial year.
Beta Drugs Limited has scheduled its 21st Annual General Meeting for September 30, 2026, at its registered office in Baddi, Himachal Pradesh.
Beta Drugs Limited announced the re-appointment of its Statutory Auditor and an Executive Director. These re-appointments are effective from September 2026 and January 2027, respectively.
Beta Drugs Limited announced its board meeting outcome, covering AGM arrangements, auditor appointments, and the re-appointment of its Whole-Time Director, Ashutosh Shukla.
Beta Drugs Limited has scheduled a board meeting for September 3, 2026. The agenda includes fixing the 21st AGM details and approving the Director’s Report.
Beta Drugs Limited approved the allotment of 35,383 bonus equity shares. These shares were issued to holders of Compulsorily Convertible Debentures following their conversion.
Beta Drugs Limited submitted its quarterly Monitoring Agency Report for June 2026. The report tracks the utilization of Rs. 117.01 Crore raised via preferential issues.
Beta Drugs Ltd. reports Q1-FY27 revenue of INR 1,255 Mn with 21.83% EBITDA margin. Diversifying beyond core oncology into IVF via Nivian acquisition.
Beta Drugs submitted revised Limited Review Reports for the quarter ended June 2026, correcting the omission of UDINs as requested by the exchange.
Beta Drugs scheduled a board meeting for July 20, 2026. The board will review unaudited quarterly financial results for the period ended June 2026.
Beta Drugs Ltd clarified to the exchange that no undisclosed price-sensitive information caused the recent price movement. The share price change is purely market-driven.
Beta Drugs Limited completed the acquisition of a 66.09% stake in Nivian Lifesciences Private Limited. The target company became a subsidiary effective April 2026.
Beta Drugs Limited approved the allotment of 6,65,314 equity shares following debenture conversion. This routine capital action follows a 2024 agreement with institutional investors.
Beta Drugs Limited allotted 6,65,314 equity shares upon conversion of CCDs on May 25, 2026. This increases the company's paid-up share capital to ₹11.09 Crore.
Beta Drugs delivered record EBITDA but missed revenue guidance due to delayed export tenders and strategic withdrawal from the low-margin Platin segment.
Beta Drugs delivered FY26 revenue of ₹385 Cr with a shift towards high-margin branded oncology (36% of mix) and 22.57% EBITDA margin.
Beta Drugs Limited reported utilization of ₹117.01 Crore raised through preferential issues. The Monitoring Agency confirms funds were deployed for subsidiary upgradation and R&D.
Beta Drugs Ltd reported revenue from operations of ₹939,649,419 Cr (+0.2% YoY) and net profit of ₹90,489,234 Cr (+0.2% YoY) for Q4 FY26.
Beta Drugs reported consolidated annual revenue of ₹396.0 Crore, representing 7.4% growth. Net profit stood at ₹41.5 Crore as the company continues its Vision 2030 expansion.
Beta Drugs scheduled a board meeting for May 14, 2026, to review audited annual financial results. The trading window remains closed until May 16.
Beta Drugs Limited has allotted 2,83,668 equity shares via a preferential issue at ₹1,712.49 per share, raising approximately ₹4.86 Crore. The shares were issued to 33 investors on a pari-passu basis, increasing the company's paid-up share capital to ₹10.42 Crore.
Beta Drugs Limited allotted 2,83,668 equity shares at ₹1712.49 each, totaling ₹48.58 Crore. This issuance is part of the consideration for the acquisition of Nivian Lifesciences Private Limited, expanding the company's equity base.
Beta Drugs Limited achieved regulatory milestones in Azerbaijan and the Philippines. The company received generic drug approvals for two brands in the Philippines and successfully completed an Azerbaijan Ministry of Health inspection. These developments enhance access to CIS and Southeast Asian markets, supporting future export revenue growth.
Beta Drugs Limited promoters, including Rahul Batra and Varun Batra, have disclosed a nil-pledge status for the period ending March 31, 2026. The filing confirms that no shares held by the promoter group are encumbered or pledged, reflecting strong promoter ownership stability.
Beta Drugs Limited clarified to NSE that recent significant share price movements are purely market-driven. The company confirmed there is no undisclosed price-sensitive information or material announcements pending. Beta Drugs maintains compliance with SEBI transparency regulations and continues to monitor market activity.
Beta Drugs Limited submitted its quarterly compliance certificate for the period ended March 31, 2026. The certificate confirms that security certificates received for dematerialisation were processed and the name of the depositories substituted in the register of members within prescribed timelines. This is a routine regulatory filing with no material financial impact.
Beta Drugs Limited provided a shareholding clarification regarding its proposed preferential issue. Following the issuance of equity shares and conversion of CCDs, the total share capital will increase to 1,10,85,872 shares, with promoter holding adjusting from 64.63% to 59.10%.